Cardionovum

Be up
to date.

Latest press release

If you were unable to attend the webinar "Aperto® DCB: A Glimpse of the Future Today,” you can still view the session.

 

Please click here to access the video.

 

Thanks to Dr. Kitrou from Patras, Prof. Tozzi from Varese, and Dr. Shahverdyan from Hamburg, you will have the opportunity to:

 

  • Gain a comprehensive overview of the DCB’s role in the Vascular Access landscape today and in the future;
  • Receive the latest clinical update on Aperto® and its cost-benefit implications;
  • Participate in a practical session with a discussion on challenging cases.

Dr. Testa (Milan, Italy) discusses the results of the XLIMIT Trial with Radcliffe at the EuroPCR 2024 congress in Paris, France.

 

In this video interview, Dr. Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria, and clinical outcomes.

 

Specifically, the 6 to 9 months follow-up results showed that the XLIMUS® DES was comparable to the Synergy™ DES on both primary endpoints (in-stent neointimal percent volume obstruction and in-stent neointimal volume). No difference was also found with respect to the secondary OCT endpoints as well as for clinical endpoints.

 

The study results confirm that the biological interaction of the XLIMUS® and Synergy™ DES with the coronary artery is comparable, and that translates in very reassuring OCT parameters at follow-up: as such, the XLIMUS® DES is non-inferior to the Synergy™ DES.

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2024 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dr. Ielasi explains the technology behind the Restore® drug-coated balloon (Cardionovum®) and its advantages. Furthermore, he offers a comprehensive analysis of the HYPER Study, elucidating its methodology, participant selection criteria, and clinical outcomes.

 

Specifically, the 1-year outcomes revealed that DoCE was 3.7%. Subsequently, an extensive 2-year follow-up demonstrated a DoCE rate of 4.6%, maintaining stability up to the 3-year analysis.

 

In conclusion, the HYPER Study demonstrated that the hybrid approach combining a drug eluting stent with the Restore® DEB is not only feasible but also associated with very high procedural success and a remarkably low 1-year DoCE rate. These favourable results remain consistent over the 3-year follow-up period.

Cardionovum® is present in the Archives of Internal Medicine Research (ISSN: 2688-5654) in the article entitled “Drug Coated Balloon Angioplasty for Dysfunctional Arteriovenous Fistula: A New Standard-of-Care in the Horizon?”.

 

In this recent article, Dr. Lichtenberg unveils the role of DCBs in Vascular Access Management, and an entire chapter is devoted to our Aperto® OTW drug coated balloon with an extensive overview of its main technical features and clinical results.

 

The Archives of Internal Medicine Research (ISSN: 2688-5654) is an open access peer-reviewed journal providing innovative and clinically relevant research platform for physicians, practitioners, pathologists, pharmacologist and students in general internal medicine and internal medicine subspecialties with an Impact Factor 3.6.

We are glad to announce Cardionovum®'s prestigious recognition as one of the Top 10 Cardiovascular Solutions Companies in Europe for 2023 by MedTech Outlook.

 

This acknowledgment reflects our unwavering commitment to innovation and excellence within the field of cardiovascular solutions.

Being included in this list is a proof to our Team's dedication and the impact of our pioneering technologies.

 

In addition, we are honored to be present in the November edition of MedTech Outlook magazine, providing an in-depth article that delves into our contributions in driving innovation to improve patients' lives.

Cardionovum® is present in the Vascular News’s November edition with an article in which Prof. Tozzi (Varese, Italy) shares the clinical outcomes of the Aperto 600 Study, in which more than 600 Aperto® DCBs have been used in ArteriousVenous Fistula (AVF) and ArteriousVenous Graft (AVG), including a large number of Central Vein Stenosis (CVS).

Upcoming events

Cardionovum® at CIRSE 2024

Cardionovum® is glad to inform that will attend CIRSE 2024.

Location:

CCL – Lisbon Congress Centre
Praça das Industrias 1
1300-307 Lisbon
Portugal

Date: Sep 14, 2024–Sep 18, 2024

Latest events

Cardionovum at EuroPCR 2022

Cardionovum invites you to participate in 3 scientific sessions:

  • XLIMT trial with Dr. Luca Testa.
    Primary end point presentation.

    Available online:
    Poster Lab section
    17th-20th May

  • Restore SVD randomized trial with Dr. Changdong Guan.
    4 Year follow up presentation.

    On demand section:
    17th-20th May

  • HYPER study with Dr. Alfonso Ielasi.
    Primary end point presentation.

    In person presentation:
    Thursday 19th, 10:30- 12:00h Room Maillot

You are welcome to visit us at booth F6

Date: May 17, 2022–May 20, 2022

Location: France Palais des congrès, Paris

Learn more >>

Cardionovum GmbH at: "A glimpse into the future"

Cardionovum GmbH participates in:
The 1st symposium of interventional & clinical cardiology "A glimpse into the future". Dominican Society of Cardiology.

You are cordially invited to visit our booth.

Location: Convention Center, UTESA, Santiago, Dominican Republic

Download the program here (PDF)

Date: Jan 28, 2022–Jan 29, 2022

Cardionovum at BSIR

Cardionovum participates
together with their partner in the UK;
Aquilant a Health-Care 21 Company
At the BSIR; British Society of Interventional Radiology

You are welcome to visit us at booth Nr. 15

Location: Glasgow, UK

Date: Dec 08, 2021–Dec 10, 2021

go top